These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24008177)

  • 21. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs.
    Rawal RK; Murugesan V; Katti SB
    Curr Med Chem; 2012; 19(31):5364-80. PubMed ID: 22998569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
    PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors.
    Sharma D; Lau AJ; Sherman MA; Chang TK
    Biochem Pharmacol; 2013 Jun; 85(11):1700-11. PubMed ID: 23583259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rilpivirine: The Key for Long-term Success.
    Viciana P
    AIDS Rev; 2017; 19(3):156-166. PubMed ID: 29066858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
    Kontorinis N; Dieterich DT
    Semin Liver Dis; 2003 May; 23(2):173-82. PubMed ID: 12800070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.
    Sluis-Cremer N; Wainberg MA; Schinazi RF
    Future Microbiol; 2015; 10(11):1773-82. PubMed ID: 26517190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
    DeStefano JJ
    Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients infected with HIV.
    Dailly E; Allavena C; Deslandes G; Bouquie R; Jolliet P; Raffi F
    Curr Clin Pharmacol; 2014; 9(4):399-403. PubMed ID: 24218996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
    Theys K; Camacho RJ; Gomes P; Vandamme AM; Rhee SY;
    Clin Microbiol Infect; 2015 Jun; 21(6):607.e1-8. PubMed ID: 25704446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
    Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
    AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Non-nucleoside reverse transcriptase inhibitors].
    Joly V; Yeni P
    Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
    Melikian GL; Rhee SY; Varghese V; Porter D; White K; Taylor J; Towner W; Troia P; Burack J; Dejesus E; Robbins GK; Razzeca K; Kagan R; Liu TF; Fessel WJ; Israelski D; Shafer RW
    J Antimicrob Chemother; 2014 Jan; 69(1):12-20. PubMed ID: 23934770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
    De Clercq E
    Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
    Smith PF; DiCenzo R; Morse GD
    Clin Pharmacokinet; 2001; 40(12):893-905. PubMed ID: 11735608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
    Zhang Z; Hamatake R; Hong Z
    Antivir Chem Chemother; 2004 May; 15(3):121-34. PubMed ID: 15266894
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.